John Bausher, MD
Family Medicine · Aberdeen, WANPI 1033207824
Payments from drug & device makers
Across 267 payments — averaging $16.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$748
- GSK$362
- Pfizer$322
- AstraZeneca$313
- Novo Nordisk$293
- Boehringer Ingelheim$249
- plus $2K from 27 others
What the payments were for
- Food & beverage$4,30097%
- Education$1233%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 56 | $748 |
| GSK | 18 | $362 |
| Pfizer | 15 | $322 |
| AstraZeneca(2 entities) | 19 | $313 |
| Novo Nordisk | 23 | $293 |
| Boehringer Ingelheim | 11 | $249 |
| AbbVie(2 entities) | 12 | $245 |
| Johnson & Johnson | 18 | $197 |
| Sanofi-aventis U.S. LLC | 13 | $192 |
| Bayer | 10 | $170 |
| Novartis | 8 | $165 |
| Sanofi Pasteur Inc. | 7 | $138 |
| Phathom Pharmaceuticals, Inc. | 6 | $137 |
| Lilly USA, LLC | 8 | $131 |
| Dexcom, Inc. | 8 | $106 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $102 |
| Abbott | 4 | $77 |
| Mylan Specialty L.p. | 4 | $67 |
| Astellas Pharma US Inc | 2 | $45 |
| Viatris Specialty LLC | 2 | $44 |
| E.r. Squibb & Sons, L.L.C. | 2 | $42 |
| Otsuka America Pharmaceutical, Inc. | 2 | $40 |
| Shield Therapeutics Inc | 2 | $39 |
| Arbor Pharmaceuticals, Inc. | 2 | $27 |
| Teva Pharmaceuticals USA, Inc. | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $21 |
| Vanda Pharmaceuticals Inc. | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $21 |
| Exact Sciences | 1 | $20 |
| Merck | 1 | $19 |
| Nevro Corp. | 1 | $17 |
| Sunovion Pharmaceuticals Inc. | 1 | $17 |
| Hologic Sales And Service, LLC | 1 | $15 |
How this compares
$4,423 in reported general payments places this provider in the 90th percentile of 2,275 family medicine providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 136 | $110,482 |
| JardianceEmpagliflozin | 138 | $105,588 |
| OtezlaApremilast | 17 | $89,788 |
| TrulicityDulaglutide | 76 | $87,847 |
| OzempicSemaglutide | 38 | $35,398 |
| XareltoRivaroxaban | 20 | $19,834 |
| JanuviaSitagliptin Phosphate | 15 | $17,116 |
| MounjaroTirzepatide | 15 | $15,161 |
| Aimovig AutoinjectorErenumab-Aooe | 15 | $12,610 |
| Tresiba Flextouch U-100Insulin Degludec | 20 | $12,405 |
| EntrestoSacubitril/Valsartan | 15 | $11,249 |
| FarxigaDapagliflozin Propanediol | 22 | $10,882 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $9,368 |
| Repatha SureclickEvolocumab | 16 | $8,660 |
| LinzessLinaclotide | 14 | $7,528 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $322 | $114,795152 claims |
| Boehringer IngelheimJardiance | $249 | $105,588138 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $131 | $103,00891 claims |
| AmgenOtezla | $748 | $89,78817 claims |
| Novo NordiskOzempic | $293 | $35,39838 claims |
| Johnson & JohnsonXarelto | $197 | $19,83420 claims |
| MerckJanuvia | $19 | $17,11615 claims |
| NovartisEntresto | $165 | $11,24915 claims |
| AstraZenecaFarxiga | $313 | $10,88222 claims |
| GSKBreo Ellipta, Shingrix | $362 | $9,84534 claims |
| AbbVieLinzess | $245 | $7,52814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,275 family medicine providers in Washington.
Other family medicine in Aberdeen
- Anton GraschWenatchee$5.3M
- Gaylon KippBellevue$4.8M
- Steven KasterWenatchee$4M
- Angela EakinSpokane$3M
- Jonathan StabenCheney$2.5M
- Emily ZaragozaSeattle$1.9M
- Brad FrandsenPort Orchard$1.7M
- Kevin HatfieldSeattle$527K
- Steven SmithAuburn$438K
- John RobinsonEdmonds$425K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.